CareAcademy Announces Innovative Research Initiative with the Center for Community Health & Evaluation of Kaiser Permanente Washington to Evaluate Impact of Caregiver Training on Health Outcomes
BOSTON--(BUSINESS WIRE)-- CareAcademy, the leading provider of caregiver training and compliance technology, is proud to announce a collaborative research project with the Center for Community Health and Evaluation (CCHE). This initiative will evaluate CareAcademy's newly developed Safety Specialist Certificate Program (SSCP) and its impact on caregiver confidence, patient outcomes, and healthcare cost savings.
CCHE, known for its rigorous yet practical evaluation methods, brings decades of experience in health-related program assessments across the United States. Their mission to improve community health aligns seamlessly with CareAcademy's commitment to empowering caregivers and enhancing care delivery.
The SSCP training intervention combines existing CareAcademy modules with a focus on increasing medication adherence and reducing rehospitalizations among persons receiving care (PRC). While CareAcademy's data shows that caregivers report heightened confidence after training, this study will be the first formal evaluation to measure the program's impact on PRC outcomes.
Helen Adeosun, CEO of CareAcademy, expressed enthusiasm for the partnership: 'At CareAcademy, we believe in the transformative power of education for caregivers. This research will provide valuable insights into how our training directly improves patient care and health outcomes. This new information is a game changer for our entire industry and elevates the value of caregivers enabling health.
Partnering with CCHE allows us to take a critical step forward in demonstrating the measurable impact of caregiver education.'
Maggie Smith, Director at CCHE, added 'We are excited to collaborate with CareAcademy on this important evaluation. Caregiver training plays a vital role in supporting community health, and this evaluation will help us understand how structured education programs can enhance caregiver effectiveness and improve health outcomes for patients across diverse care settings.'
The evaluation, slated for implementation this year, will engage CareAcademy's key partner, Sharecare, which connects families nationwide with caregivers through its tech-enabled home care services. CCHE's research will include:
Caregiver Experience and Outcomes: Understanding how caregivers perceive the SSCP training and its effects on their professional confidence, stress levels, and job satisfaction.
Patient Outcomes: Assessing PRC health outcomes, including hospital readmission rates, medication adherence, and overall quality of life.
Cost Savings: Modeling potential long-term cost savings through improved patient health outcomes.
About CCHE
The Center for Community Health and Evaluation (CCHE), part of Kaiser Permanente Washington Health Research Institute, designs and evaluates health-related programs and initiatives across the United States. CCHE's mission is to improve the health of communities with collaborative approaches to planning, assessment, and evaluation.
About Sharecare
Sharecare is a digital healthcare company that delivers software and tech-enabled services to stakeholders across the healthcare ecosystem to help improve care quality, drive better outcomes, and lower costs. Through its data-driven AI insights, evidence-based resources, and comprehensive platform – including benefits navigation, care management, home care resources, health information management, and more – Sharecare helps people easily and efficiently manage their healthcare and improve their well-being. Across its three business channels, Sharecare enables health plan sponsors, health systems and physician practices, and leading pharmaceutical brands to drive personalized and value-based care at scale. To learn more, visit www.sharecare.com.
About CareAcademy
CareAcademy is a leading care enablement platform dedicated to transforming caregiver education and empowering caregivers to deliver exceptional health outcomes. By offering compliance and audit automation technology, actionable analytics, and streamlined training management of an engaging content library, CareAcademy is accelerating the world's transition to a caregiver-centric healthcare system. Founded in 2016 and based in Boston, CareAcademy has trained more than 800,000 caregivers and is trusted by more than 2,000 home care, home health, senior living, and hospice providers nationwide. To learn more, visit www.careacademy.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19-05-2025
- Yahoo
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine ( a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products. AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety. Immunogenicity Indicators Significantly Outperform International Benchmarks According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines. Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential. Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually. mRNA Platform Capabilities Continue to Lead the Industry The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines. Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential. Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging. In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership. As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential. View original content: SOURCE AIM Vaccine
Yahoo
19-05-2025
- Yahoo
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine ( a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine has received clinical trial approval from PRC's Center for Drug Evaluation (CDE), following its U.S. FDA clearance in March this year. The vaccine has demonstrated significantly stronger humoral and cellular immunity compared to international benchmark products. AIM Vaccine's mRNA platform capabilities are once again in the spotlight. Fosun International Securities recently noted in a research report that AIM's mRNA shingles vaccine could challenge the existing market landscape with its potential for superior efficacy and safety. Immunogenicity Indicators Significantly Outperform International Benchmarks According to the announcement, preclinical trial results from third-party testing institutions demonstrate that AIM's mRNA shingles vaccine shows significantly higher specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescent antibody (FAMA) titers compared to internationally marketed recombinant subunit control vaccines. Furthermore, there are currently no mRNA-based shingles vaccines approved for marketing globally. According to recently published industry references, the vaccination rate for shingles vaccines among PRC's target population is less than 1%, indicating enormous growth potential. Fosun International Securities' research report analysis mentions that as PRC's first company to establish a complete mRNA vaccine R&D system, its technological approach successfully avoids existing shingles vaccine patent barriers, creating favorable conditions for entering the global market projected to reach US$23.9 billion annually. mRNA Platform Capabilities Continue to Lead the Industry The competition in mRNA technology platforms between domestic and international companies has reached intensity comparable to an arms race, with infectious disease and cancer vaccines being the key battlegrounds. AIM Vaccine leads the industry through breakthrough progress in infectious disease vaccines. Fosun International Securities' research report released in late March pointed out that AIM Vaccine holds a leading position in PRC's mRNA vaccine field, having obtained 11 clinical approvals across 6 countries, including 2 FDA approvals in the U.S. Its platform technology has been validated by favorable safety and efficacy clinical data from over 10,000 subjects. This latest approval for its mRNA shingles vaccine in PRC further highlights the company's leading position in next-generation vaccine technology and rapid commercialization potential. Some industry observers believe that if PRC companies can continue to overcome core patents, expand indications, and deepen international cooperation, mRNA technology may become a hallmark area for PRC's biopharmaceutical industry to achieve technological leapfrogging. In this cutting-edge field, AIM Vaccine has not only secured clinical approvals in both PRC and the U.S. for its mRNA shingles vaccine and mRNA RSV vaccine, but also has its next-generation mRNA rabies vaccine and mRNA influenza vaccine in pre-IND review and preclinical studies respectively, demonstrating the platform's strong extensibility and laying a solid foundation for sustained development and market leadership. As analyzed by multiple investment institutions, AIM Vaccine combines innovative technology, industry leadership, and growth potential, making it a highly attractive investment choice. They remain optimistic about the company's development prospects driven by industry recovery and new products, and believe its valuation has significant upside potential. View original content: SOURCE AIM Vaccine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-05-2025
- Business Wire
CareAcademy Announces New Product Suite to Address the Direct Care Worker Shortage and Transform Caregiver Recruitment
BOSTON--(BUSINESS WIRE)-- CareAcademy, the leading provider of caregiver training and compliance technology, announced today a bold new product initiative designed to address one of the most pressing challenges in healthcare: the nationwide shortage of direct care workers. This new product suite, CareSync by CareAcademy, reimagines how direct care workers enter, move through, and thrive in the post-acute care industry. Built for both employers and caregivers, the strategic vision includes three core components: Find Employees – Recruit new candidates who are credentialed or a new talent pool actively looking to enter the field of direct care work through an ecosystem of interested and available individuals. Verify Records – Seamlessly verify and download caregiver certificates and training logs to simplify hiring decisions. Onboard Quickly – Transfer caregiver training records, through Shared Training History, in real time to eliminate redundant training, reduce training costs, and accelerate time-to-work. The first capability released will be native in the CareAcademy Training Platform and will be available in early July 2025. Through Shared Training History, employers will gain the ability to automatically access and apply training histories from caregivers with prior experience—dramatically reducing onboarding bottlenecks and costs. 'For too long, onboarding inefficiencies and record silos have kept capable caregivers on the sidelines,' said Helen Adeosun, CEO and Founder of CareAcademy. 'CareSync by CareAcademy brings us closer to a future where entering the caregiving field is more accessible, and finding work is as intuitive as using LinkedIn.' CareAcademy's vision is to build a connected, credentialed, and elevated direct care workforce. By integrating recruiting, credential verification, and onboarding into one seamless experience, CareAcademy is unlocking a broader, more diverse talent pool—and accelerating pathways into the direct care industry. For caregivers, this technology opens doors to new job opportunities and reduces barriers to employment. For employers, it offers a modern, scalable solution to reduce hiring friction, close staffing gaps, and find greater operational efficiency. About CareAcademy CareAcademy is a leading care enablement platform dedicated to transforming caregiver education and empowering caregivers to deliver exceptional health outcomes. By offering compliance and audit automation technology, actionable analytics, and streamlined training management of an engaging content library, CareAcademy is accelerating the world's transition to a caregiver-centric healthcare system. Founded in 2016 and based in Boston, CareAcademy has trained more than 800,000 caregivers and is trusted by more than 2,000 home care, home health, senior living, and hospice providers nationwide. To learn more, visit
